CIC
HELP

Chase Investment Counsel’s Helus Pharma Inc. Common Stock HELP Stock Holding History

Chase Investment Counsel’s Portfolio HELP Stock Details HELP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-329
Closed -$15K – 119
2021
Q4 		$15K Hold
329
– – 0.01% 114
2021
Q3 		$27K Buy
+329
New +$28.8K 0.01% 101

Other funds holding HELP

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCC
Perry Creek Capital New York $218M AUM 18.4% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
T
TCWP Beachwood, Ohio $40.8M AUM 31.25% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Chase Investment Counsel's HELP Position: Q1 2022 in Review

Chase Investment Counsel sold out of Helus Pharma Inc. Common Stock (HELP) in Q1 2022, closing a stake of 329 shares — an estimated $15K sold.

Chase Investment Counsel first reported a position in HELP in Q3 2021 and held it in 2 quarters. The position peaked at $27K in Q3 2021. 51 funds tracked by Wall St. Rank hold HELP as of Q1 2022.

  • Chase Investment Counsel reported no remaining Helus Pharma Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Chase Investment Counsel sold 329 Helus Pharma Inc. Common Stock shares in Q1 2022, an estimated $15K.
  • Chase Investment Counsel first reported a position in Helus Pharma Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • Chase Investment Counsel's Helus Pharma Inc. Common Stock position peaked at $27K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q1 2022.

Based on Chase Investment Counsel's 13F filing for Q1 2022, filed 21 Apr 2022.